Anderson-Fabry disease. Conclusion


  • Giovanni Duro Centro di Ricerca e Diagnosi Malattie da Accumulo Lisosomiale, Istituto di Biomedicina e Immunologia Molecolare ���A. Monroy��� (IBIM), Consiglio Nazionale delle Ricerche (CNR), Palermo
  • Marco Lombardi Nefrologia e Dialisi, Ospedale del Mugello, A.S. Toscana Centro, Borgo San Lorenzo (FI)



Fabry disease, Lyso-Gb3, alfa-GAL A


Fabry disease is a hereditary, progressive and multisystemic disorder characterized by variable clinical manifestations and a course that can lead to the death of the patient between the fourth and fifth decades of life if not promptly diagnosed. It is a metabolic, lysosomal storage disorder which is due to the functional deficit of the enzyme alpha-galactosidase A (alfa-GAL A). The deficit alters the metabolism of some glycosphingolipids, mainly globotriaosylceramide (Gb3) and lyso-Gb3 (the deacetylated form), causing their storage in lysosomes of various cell types, especially those of the vascular endothelium. The knowledge of this disease has improved in recent years and it is increasingly clear that it could be a more complex disorder than previously thought and that also other factors are likely to be involved in the onset of its symptoms. (aiaf)


Download data is not yet available.



How to Cite

Duro, G., & Lombardi, M. (2017). Anderson-Fabry disease. Conclusion. Giornale Di Clinica Nefrologica E Dialisi, 29(Suppl. 1), S35-S36.



AIAF Onlus - In collaboration with Associazione Italiana Anderson-Fabry


Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>